Safety and efficacy of rapid (1,000 mg in 1 hr) intravenous iron dextran for treatment of maternal iron deficient anemia of pregnancy

被引:36
|
作者
Wong, Lee [1 ]
Smith, Samuel [1 ]
Gilstrop, Marisa [2 ]
Derman, Richard [2 ]
Auerbach, Sarah [3 ]
London, Nicola [1 ]
Lenowitz, Steven [1 ]
Bahrain, Huzefa [4 ]
McClintock, Jessica [1 ]
Auerbach, Michael [5 ]
机构
[1] MedStar Franklin Sq Med Ctr, Dept Obstet & Gynecol, Baltimore, MD USA
[2] Christiana Care Hlth Syst, Dept Obstet & Gynecol, Newark, DE USA
[3] West Virginia Sch Osteopath Med, Lewisburg, WV USA
[4] Auerbach Hematol & Oncol, Baltimore, MD USA
[5] Georgetown Univ, Sch Med, Dept Med, Washington, DC USA
关键词
FERRIC CARBOXYMALTOSE; ORAL IRON; WEIGHT; SUCROSE; HEMOGLOBIN;
D O I
10.1002/ajh.24361
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Maternal iron deficiency anemia (IDA) is associated with risk of adverse perinatal outcomes. Oral iron is recommended to reverse anemia, but has gastrointestinal toxicity and frequent non-adherence. Intravenous (IV) iron is reserved for intolerance of, or unresponsiveness to, oral therapy, malabsorption, and severe anemia (1% with hemoglobin [Hgb] levels <7 g/dL). With rare (<100 per one million) adverse events (AEs) ability to infuse a sufficient dose of low molecular weight iron dextran (LMWID) over 60 min, LMWID is an attractive option. This study demonstrated safety and efficacy of rapid IV infusion of 1,000 mg LMWID to gravidas with moderate to severe IDA. An observational treatment study of 1,000 mg LMWID administered over 1 hr for IDA in 189 consecutive, unselected second and third trimester gravidas after oral iron failure was conducted. All received a test dose of 25 mg LMWID and were monitored for AEs during the 60-min infusion. No premedication was administered unless more than one drug allergy or asthma was present in which case IV methylprednisolone was administered. All were followed through pregnancy and delivery. Monitored parameters included Hgb, mean corpuscular volume, serum ferritin, and percent transferrin saturation. About 189 subjects received 1,000 mg LMWID. No serious AEs occurred. About 2% experienced transient infusion reactions. Hgb improved by 1-1.9 g/dL in 82% and >= 2 g/dL in 24%. Second trimester treatment was not associated with greater Hgb improvement than third trimester treatment. Anemia resolved in 95%. Administration of a single large dose of IV LMWID was effective, safe, and convenient. (C) 2016 Wiley Periodicals, Inc.
引用
收藏
页码:590 / 593
页数:4
相关论文
共 39 条
  • [21] Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: A randomized controlled trial
    Kivitz, AJ
    Greenwald, MW
    Cohen, SB
    Polis, AB
    Najarian, DK
    Dixon, ME
    Moidel, RA
    Green, JA
    Baraf, HSB
    Petruschke, RA
    Matsumoto, AK
    Geba, GP
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2004, 52 (05) : 666 - 674
  • [22] Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia
    Mahevas, Matthieu
    Ebbo, Mikael
    Audia, Sylvain
    Bonnotte, Bernard
    Schleinitz, Nicolas
    Durand, Jean-Marc
    Chiche, Laurent
    Khellaf, Medhi
    Bierling, Philippe
    Roudot-Thoraval, Francoise
    Godeau, Bertrand
    Michel, Marc
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (10) : 858 - 861
  • [23] Efficacy and safety of intravenously administered iron sucrose with and without adjuvant recombinant human erythropoietin for the treatment of resistant iron-deficiency anemia during pregnancy
    Breymann, C
    Visca, E
    Huch, R
    Huch, A
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2001, 184 (04) : 662 - 667
  • [24] A randomized double-blind pilot study to evaluate the efficacy, safety, and tolerability of intravenous iron versus oral iron for the treatment of restless legs syndrome in patients with iron deficiency anemia
    Short, Vanessa
    Allen, Richard
    Earley, Christopher J.
    Bahrain, Huzefa
    Rineer, Stella
    Kashi, Kiumarce
    Gerb, Jesse
    Auerbach, Michael
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (06) : 1077 - 1083
  • [25] Value of erythrocyte ZPP (zinc protoporphyrin) and MCV in differential diagnosis of β-thalassemia minor and iron deficiency anemia (a study of 1,000 patients)
    Keyhani, M
    Hajian, H
    Shabari, FR
    BLOOD, 2002, 100 (11) : 5B - 5B
  • [26] IRON PROTEIN SUCCINYLATE IN THE TREATMENT OF IRON-DEFICIENCY - CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL ON OVER 1,000 PATIENTS
    LIGUORI, L
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1993, 31 (03) : 105 - 123
  • [27] INTRAVENOUS IRON THERAPY FOR TREATMENT OF ANEMIA DURING PREGNANCY IS ASSOCIATED WITH IMPROVED MATERNAL QUALITY OF LIFE, LESS POSTNATAL DEPRESSION AND LONGER BREASTFEEDING
    Khalafallah, A.
    Dennis, A.
    HAEMATOLOGICA, 2013, 98 : 177 - 177
  • [28] Safety and Efficacy of High Dose Intravenous Ferric Carboxymaltose vs. Standard Medical Care in the Treatment of Iron Deficiency Anemia
    Barish, Charles
    Bregman, David
    Butcher, Angelia
    Koch, Todd
    Morris, David
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S406 - S407
  • [29] Evaluation of the efficacy and safety of intravenous infusion of ferric derisomaltose in the treatment of iron deficiency anemia:a single-center retrospective analysis
    丁少雪
    China Medical Abstracts(Internal Medicine), 2024, 41 (03) : 184
  • [30] Efficacy and safety of adjuvant recombinant human erythropoietin and ferrous sulfate as treatment for iron deficiency anemia during the third trimester of pregnancy
    Rodrigo Sanchez-Gonzalez, Luis
    Enrique Castro-Melendez, Simon
    Cristina Angeles-Torres, Alejandra
    Castro-Cortina, Nohemi
    Escobar-Valenci, Alfredo
    Quiroga-Garza, Alejandro
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2016, 205 : 32 - 36